1/ 🎬 You can now turn a paper into beautiful slides—then into a narrated video presentation—all using AI.
I just did it with our new NEJM AI paper (led by @narges_razavian ). 5 minutes for the full video, 15 slides, narration synced to each one. Here's how 🧵
🎓 Medical students: AI is transforming medicine. EIPM was at Weill Cornell's Area of Concentration fair—we have projects in deep learning on pathology images, genomics/proteomics, and multi-agent AI systems. All levels welcome. Reach out to apply AI to real patient problems.
1/6 I’ve always loved the promise of AR: to bring us closer to our data. But clunky interaction often gets in the way.
My hypothesis is that voice may be the key to finally achieving that fluid connection. I built this prototype on the Apple Vision Pro to test it. Here's a demo:
AI is challenging the paradigm of "undruggable" cancer targets. Our new Nature Biotechnology comment outlines how AI-driven approaches, from modeling protein complexes to designing novel biologics, can unlock these intractable proteins nature.com/articles/s41587-0…
Fiction can be a powerful guide for how we deploy technology. "The Dream Hotel" by @LailaLalami is a compelling cautionary tale about the societal risks of predictive AI, highlighting why building ethical, transparent systems is so important. Read more at open.substack.com/pub/profel…
Autonomous surgery once seemed like a distant dream. Now, AI can learn complex surgical steps by imitating experts. Imagine scaling this with thousands of recorded surgical videos. I explore this milestone for AI in the physical world on my Substack: open.substack.com/pub/profel…
AI co-scientists excel at summarizing literature. But real scientific discovery comes from interpreting complex raw data and building conceptual models. The next gen of AI partners must learn to do the same. My thoughts on what's next for AI in science: open.substack.com/pub/profel…
Congratulations to Ben Hopkins & his team at the Englander Institute on their new @CellRepMed paper. Their work shows a rigosertib + taselisib combo effectively targets ovarian cancer in preclinical models. A smart, two-pronged attack on a tough disease. cell.com/action/showPdf?pii=…
Excited to share our comprehensive pan-cancer analysis of the tumor microenvironment. Led by @BhavneetBhinder, @PaulSpellman13 & collaborators, we mapped the TME of >10,000 tumors, revealing 41 distinct immune/stromal patterns and their link to survival nature.com/articles/s41598-0…
For the few years I've been covering jobs reports, and one sector typically rises above the rest, quietly hiring by the thousands: Health care.
How taking care of humans became the biggest employer in America, and what it means for the rest of us.
nytimes.com/interactive/2025…
What's the path forward for AI in the cancer clinic? Our @NEJM_AI review explored this question. A new paper in @NatureCancer from @jnkath's team now provides a compelling example with a "tool-using" AI agent.
open.substack.com/pub/profel…
I love when AI is used for breakthrough discovery. A new @MSFTResearch report details how their Skala model solves a 60-year problem in computational chemistry, enabling a 'cascade of accuracy' to faster models like force fields. More on this work here: microsoft.com/en-us/research…
NYC has the talent. Now it needs the infrastructure. To become the true capital of AI, we must build our own models, share data, and invest in massive compute power. My thoughts on how NYC can move from AI adopter to AI inventor profelemento.substack.com/p/…
I am incredibly sad to learn of the passing of Atul Butte. He was a true giant in our field and a profound inspiration to me and countless others. His vision and contributions have fundamentally shaped biomedical data science. I will miss his boundless energy. RIP my friend.
Great to connect with the Heal Italia Foundation at the Englander Institute this week. We are united in our mission to advance precision medicine for patients, and I believe building these global partnerships is the key to accelerating science !
If the convergence of oncology, virology, and AI intrigues you, check out my quick interview with amfAR’s Andrea Gramatica on the hidden parallels—from AI-powered virtual patient “twins” to the long-game ambition of an AI-designed drug for every patient.
amfar.org/news/ai-cancer-and…
🚀 AI is changing software forever.
I asked Claude 3.7 Sonnet to build an iPhone app for visualizing protein interaction networks in AR—having zero experience in Swift or ARKit.
The result? Nearly 2,000 lines of functional code. 🤯
(1/🧵)
How do early lung tumors evolve? Our latest preprint, led by Junbum Kim, maps early-stage cancer at single-cell resolution, revealing two key pathways:
🦠Driven by immune activity
🛠️ Driven by fibrosis
These insights could refine detection & treatment
biorxiv.org/content/10.1101/…
Wow! GLP-1 receptor agonists now linked to a substantial reduction in incidence for 10 types of cancers, in patients with Type 2 Diabetes !jamanetwork.com/journals/jam…
Exciting ! @cornell to team up with 5 other academic partners, New York State, and philanthropic groups to create a new massive AI Research Center! nytimes.com/2024/01/08/nyreg…
BTG1 mutation yields supercompetitive B cells primed for malignant transformation. Very cool story led by @coraline_mly @LabMelnick ! science.org/doi/10.1126/scie…
A great meeting of the NCI-funded Genomic Data Analysis Network. Very inspiring to get together with some of the best cancer genomic scientists and computational biologists in the country and discuss cutting-edge techniques to analyze cancer genomes !
Check out these @chronicle headlines and this is just part of the story. There’s a real and broad crisis in academia. We will need change and strong leadership to navigate the rough waters ahead of us
Quite exciting to see several papers using enhanced CRISPR-based gene editing to produce better, safer cell therapies. Natural next phase likely will use synthetic biology to create cell therapies with increasingly complex behaviors nature.com/articles/s41587-0…nature.com/articles/s41586-0…
A concise review of innovative concepts in clinical trials: master protocols, adaptive designs, and real-world data. All three unified by the promising (yet still infrequent) power of Bayesian modeling! nature.com/articles/d41573-0…
Blown away by the explosion of human brain data and how it is fueling a whole new understanding of brain disorders. Here @misicbata et al find MRI connectivity & gene expression patterns that correlate with structural defects in 21K brain disorder patients nature.com/articles/s41467-0…
Thanks to covalent drug discovery, previously ‘undruggable’ proteins such as mutant KRAS(G12C) have become druggable. In a fantastic review at @NatRevDrugDisc, @DanNomura and team summarize the booming field of emerging covalent drug discovery techniques nature.com/articles/s41573-0…
Congrats David Baker and team on a beautiful paper showing how new membrane-permeable macrocyclic peptides can be designed computationally cell.com/cell/fulltext/S0092…. Exciting to see the parallel launch of NewCo (Vilya) with @rtnarch to seek therapeutic applications!
Vilya launches with David Baker and team and ARCH Venture Partners to push the boundaries of computational biology. Using artificial intelligence to design new medicines that would be impossible to find using conventional technologies. businesswire.com/news/home/2…
Tomorrow at Noon:
EIPM Seminar Series lecture, "The (R)evolution in the Management of #Urothelial Cancer: Progress Made and a Look into the Future," by Dr. Petros Grivas (@PGrivasMDPhD) from the @UW and @fredhutch
NEW ROOM: 302-A
Zoom mtg info emailed to #WCM staff
Smaller, more bioavailable, and less reliant on existing structural pockets than PROTAC, small molecule glues that achieve targeted protein degradation have started to enter the clinic @cenmagcen.acs.org/pharmaceuticals/…
Applying weak electric currents to different parts of the human brain using transcranial alternating current stimulation led to pronounced, durable improvements in either short-term or long-term memory nature.com/articles/s41593-0… also read @MeganMolteni's take statnews.com/2022/08/22/brai…
Monoclonal antibodies currently dominate the field of immunotherapy. Yet small molecules, including those that target innate immunity pathways, may play a key role in the future of immuno-oncology. A superb review by Rienk Offringa, Klaus Urbahns & team nature.com/articles/s41573-0…
This 2018 study found that 80% of the “most transformative” medicines approved for clinical use by the FDA could be traced back to one or several basic discoveries, which occurred on average three decades before approval! science.org/doi/10.1126/scit…
What a treat it was for me and @LabMelnick to host the amazing @ManelEsteller today at @WeillCornell & @WCMEnglanderIPM ! the contributions he and his colleagues have made to the fields of cancer epigenetics and epitranscriptomics are profound and impressive!
This @NEJM article is right - time to build a data-driven National Public Health System in the US. A small investment with a huge guaranteed payoff in saved lives, decreased disparities & cost-savings nejm.org/doi/full/10.1056/NE… by M. Hamburg @KBDeSalvo @DrKhaldun@DrMandyCohen et al
A great pleasure to visit the Mayo Clinic, the number 1 hospital in the nation. So much to learn from their highly-effective, patient-centric, collaborative approach to patient care!